Maze Therapeutics, Inc. (MAZE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.21+1.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MAZE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | |
|---|---|---|---|---|
| Revenues | ||||
| Revenues | — | — | 167.5 | — |
| Operating Expenses & Income | ||||
| R&D Expenses | 121.8 | 108.4 | 83.5 | — |
| Operating Income | (145.6) | (142.9) | 57.6 | — |
| Earnings from Continuing Operations | ||||
| EBT, Incl. Unusual Items | — | (131.1) | 53.4 | — |
| Income Tax Expense | — | — | 1.2 | — |
| Net Income | ||||
| Net Income | (133.6) | (131.1) | 52.2 | — |
| Per Share | ||||
| Basic EPS | (2.26) | (3.05) | 1.42 | — |
| Diluted EPS | (2.26) | (3.05) | 1.25 | — |
| Basic Weighted Avg Shares | 59.0 | 43.0 | 2.4 | — |
| Diluted Weighted Avg Shares | 59.0 | 43.0 | 2.7 | — |
| Supplemental | ||||
| EBIT | (145.6) | (142.9) | 57.6 | — |
| Effective Tax Rate | — | — | 2.2% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.